The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years
- PMID: 24703087
- DOI: 10.1016/j.gie.2014.02.012
The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years
Abstract
Background: Despite the vast focus of research in eosinophilic esophagitis (EoE), the natural history of untreated EoE remains undefined. Current expert consensus panels are calling for natural history studies to define long-term risks, adverse events, and progression of the disease.
Objective: To address the natural course and long-term adverse events of EoE.
Design: Retrospective, single-center study.
Setting: Tertiary-care center. A cohort of patients from the year 1988 initially diagnosed as having congenital esophageal stenosis who were later reclassified as having EoE.
Patients: Ninety-five patients, with 13 meeting entrance criteria for idiopathic EoE with follow-up >5 years.
Interventions: Anti-acids and esophageal dilation.
Main outcome measurements: Clinical response, adverse events, long-term clinical outcomes, and progression of disease.
Results: Thirteen patients (mean age at diagnosis 30.3 years, 10 male) were evaluated over a 13.6-year mean follow-up (range 5-24 years). All patients experienced daily dysphagia, with 12 presenting with food impactions. Patients were treated with esophageal dilation (64% Maloney, 34% Savary, 2.5% through-the-scope balloon) and daily anti-acids. Patients were initially treated with an average of 3.2 dilations over the first year (range 1-6) to achieve a luminal size of 15.8 mm (range 14-18 mm). They were maintained successfully with dilations every 2 years, on average, based on symptoms. Two patients not adhering to recommended dilation schedules experienced repeat impactions. One adverse event from a mucosal tear required hospitalization (1 of 157, 0.6%). Seven of 13 had Barrett's esophagus, average length 2.4 cm (range 1-4 cm), 3 on initial EGD and 4 identified over a mean duration of 9.4 years. No patient developed dysplasia or malignancy.
Limitations: Retrospective, small sample.
Conclusion: The course of EoE over a 13.6-year mean duration, although persistent, appears benign and not associated with cancer risk. A program of regular esophageal dilations based on symptom recurrence appears to be a safe, long-term treatment.
Copyright © 2014 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Comment in
-
The natural history of steroid-naïve eosinophilic esophagitis: the other end of the spectrum.Gastrointest Endosc. 2015 Dec;82(6):1136. doi: 10.1016/j.gie.2015.06.026. Gastrointest Endosc. 2015. PMID: 26614162 No abstract available.
Similar articles
-
The safety of a strict wire-guided dilation protocol for eosinophilic esophagitis.Eur J Gastroenterol Hepatol. 2014 Jul;26(7):699-703. doi: 10.1097/MEG.0000000000000103. Eur J Gastroenterol Hepatol. 2014. PMID: 24901815
-
Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes.J Pediatr Gastroenterol Nutr. 2017 May;64(5):701-706. doi: 10.1097/MPG.0000000000001336. J Pediatr Gastroenterol Nutr. 2017. PMID: 28055990 Free PMC article.
-
Safety of dilation in adults with eosinophilic esophagitis.Dis Esophagus. 2013 Apr;26(3):241-5. doi: 10.1111/j.1442-2050.2012.01363.x. Epub 2012 Jun 7. Dis Esophagus. 2013. PMID: 22676406
-
The role of endoscopy in eosinophilic esophagitis: from diagnosis to therapy.Expert Rev Gastroenterol Hepatol. 2017 Dec;11(12):1135-1149. doi: 10.1080/17474124.2017.1367664. Epub 2017 Aug 17. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28803528 Review.
-
Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.Eur J Pediatr. 2018 May;177(5):649-663. doi: 10.1007/s00431-018-3129-7. Epub 2018 Mar 17. Eur J Pediatr. 2018. PMID: 29549437 Review.
Cited by
-
Evidence-based treatments for eosinophilic esophagitis: insights for the clinician.Therap Adv Gastroenterol. 2022 Jan 19;15:17562848211068665. doi: 10.1177/17562848211068665. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35069803 Free PMC article. Review.
-
Eosinophilic Esophagitis Dilation in the Community--Try It--You will Like It--But Start Low and Go Slow.Am J Gastroenterol. 2016 Feb;111(2):214-6. doi: 10.1038/ajg.2015.433. Am J Gastroenterol. 2016. PMID: 26882944
-
Recent advances in understanding/managing eosinophilic esophagitis in adults.F1000Res. 2015 Aug 20;4(F1000 Faculty Rev):592. doi: 10.12688/f1000research.6942.1. eCollection 2015. F1000Res. 2015. PMID: 26339483 Free PMC article. Review.
-
Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management.Dig Dis Sci. 2022 Apr;67(4):1101-1115. doi: 10.1007/s10620-022-07419-6. Epub 2022 Mar 1. Dig Dis Sci. 2022. PMID: 35230577 Free PMC article. Review.
-
Advances in clinical management of eosinophilic esophagitis.Gastroenterology. 2014 Dec;147(6):1238-54. doi: 10.1053/j.gastro.2014.07.055. Epub 2014 Aug 7. Gastroenterology. 2014. PMID: 25109885 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical